Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 72

1.

Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Yang Q, Deng X, Lu B, Cameron M, Fearns C, Patricelli MP, Yates JR 3rd, Gray NS, Lee JD.

Cancer Cell. 2010 Sep 14;18(3):258-67. doi: 10.1016/j.ccr.2010.08.008. Erratum in: Cancer Cell. 2010 Oct 19;18(4):396.

PMID:
20832753
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

A CK2-dependent mechanism for degradation of the PML tumor suppressor.

Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-Feldstein J, Tempst P, Pandolfi PP.

Cell. 2006 Jul 28;126(2):269-83.

PMID:
16873060
[PubMed - indexed for MEDLINE]
Free Article
3.

BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction.

Yang Q, Liao L, Deng X, Chen R, Gray NS, Yates JR 3rd, Lee JD.

Oncogene. 2013 Jun 27;32(26):3156-64. doi: 10.1038/onc.2012.332. Epub 2012 Aug 6.

PMID:
22869143
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.

Herzer K, Weyer S, Krammer PH, Galle PR, Hofmann TG.

Cancer Res. 2005 Dec 1;65(23):10830-7.

PMID:
16322229
[PubMed - indexed for MEDLINE]
Free Article
5.

Targeting the BMK1 MAP kinase pathway in cancer therapy.

Yang Q, Lee JD.

Clin Cancer Res. 2011 Jun 1;17(11):3527-32. doi: 10.1158/1078-0432.CCR-10-2504. Epub 2011 Mar 8.

PMID:
21385929
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.

Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.

Int J Cancer. 2009 Jul 1;125(1):71-7. doi: 10.1002/ijc.24329.

PMID:
19291793
[PubMed - indexed for MEDLINE]
7.

Knocking down PML impairs p53 signaling transduction pathway and suppresses irradiation induced apoptosis in breast carcinoma cell MCF-7.

Bao-Lei T, Zhu-Zhong M, Yi S, Jun-Jie Q, Yan D, Hua L, Bin L, Guo-Wei Z, Zhi-Xian S.

J Cell Biochem. 2006 Feb 15;97(3):561-71.

PMID:
16215989
[PubMed - indexed for MEDLINE]
8.

Promyelocytic leukemia is a direct inhibitor of SAPK2/p38 mitogen-activated protein kinase.

Shin J, Park B, Cho S, Lee S, Kim Y, Lee SO, Cho K, Lee S, Jin BS, Ahn JH, Choi EJ, Ahn K.

J Biol Chem. 2004 Sep 24;279(39):40994-1003. Epub 2004 Jul 23.

PMID:
15273249
[PubMed - indexed for MEDLINE]
Free Article
9.

Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.

Kim TK, Lee JS, Oh SY, Jin X, Choi YJ, Lee TH, Lee Eh, Choi YK, You S, Chung YG, Lee JB, DePinho RA, Chin L, Kim H.

Cancer Res. 2007 Dec 1;67(23):11133-40.

PMID:
18056437
[PubMed - indexed for MEDLINE]
Free Article
10.

CK2 and PML: regulating the regulator.

Lallemand-Breitenbach V, de Thé H.

Cell. 2006 Jul 28;126(2):244-5.

PMID:
16873055
[PubMed - indexed for MEDLINE]
Free Article
11.

Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.

Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, Hanzlikova H, Vancurova M, Barath P, Bartek J, Hodny Z.

Cell Cycle. 2010 Aug 1;9(15):3085-99. doi: 10.4161/cc.9.15.12521. Epub 2010 Aug 26.

PMID:
20699642
[PubMed - indexed for MEDLINE]
Free Article
12.

CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

Scaglioni PP, Yung TM, Choi S, Baldini C, Konstantinidou G, Pandolfi PP.

Mol Cell Biochem. 2008 Sep;316(1-2):149-54. doi: 10.1007/s11010-008-9812-7. Epub 2008 Jun 20. Erratum in: Mol Cell Biochem. 2009 Jul;327(1-2):279. Choi, S C [corrected to Choi, S].

PMID:
18566754
[PubMed - indexed for MEDLINE]
13.

AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.

Li Q, He Y, Wei L, Wu X, Wu D, Lin S, Wang Z, Ye Z, Lin SC.

Oncogene. 2011 Mar 10;30(10):1194-204. doi: 10.1038/onc.2010.499. Epub 2010 Nov 8.

PMID:
21057547
[PubMed - indexed for MEDLINE]
14.

Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis.

Hayakawa F, Privalsky ML.

Cancer Cell. 2004 Apr;5(4):389-401.

PMID:
15093545
[PubMed - indexed for MEDLINE]
15.

Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.

Komura N, Asakawa M, Umezawa K, Segawa K.

Exp Cell Res. 2007 Aug 1;313(13):2753-65. Epub 2007 Apr 1.

PMID:
17585903
[PubMed - indexed for MEDLINE]
16.

BMK1 is activated in glomeruli of diabetic rats and in mesangial cells by high glucose conditions.

Suzaki Y, Yoshizumi M, Kagami S, Nishiyama A, Ozawa Y, Kyaw M, Izawa Y, Kanematsu Y, Tsuchiya K, Tamaki T.

Kidney Int. 2004 May;65(5):1749-60.

PMID:
15086914
[PubMed - indexed for MEDLINE]
17.

Big mitogen-activated kinase regulates multiple members of the MEF2 protein family.

Kato Y, Zhao M, Morikawa A, Sugiyama T, Chakravortty D, Koide N, Yoshida T, Tapping RI, Yang Y, Yokochi T, Lee JD.

J Biol Chem. 2000 Jun 16;275(24):18534-40.

PMID:
10849446
[PubMed - indexed for MEDLINE]
Free Article
19.

PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR.

Bernardi R, Guernah I, Jin D, Grisendi S, Alimonti A, Teruya-Feldstein J, Cordon-Cardo C, Simon MC, Rafii S, Pandolfi PP.

Nature. 2006 Aug 17;442(7104):779-85.

PMID:
16915281
[PubMed - indexed for MEDLINE]
20.

Tumor suppressor LATS1 is a negative regulator of oncogene YAP.

Hao Y, Chun A, Cheung K, Rashidi B, Yang X.

J Biol Chem. 2008 Feb 29;283(9):5496-509. Epub 2007 Dec 24.

PMID:
18158288
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk